Pipeline

Crossfire has several candidates in different stages of development, aimed at improving therapeutic efficacy in non-responding patient populations.

Crossfire Oncology
Crossfire Oncology

DISCOVERY

PRECLINICAL

PHASE I/II

2nd and 3rd program

2nd and 3rd program

 

 

DAC (Degrader Antibody Conjugate) platform

DAC (Degrader Antibody Conjugate) platform